Literature DB >> 10196138

Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction.

J C Chow1, D W Young, D T Golenbock, W J Christ, F Gusovsky.   

Abstract

TLR4 is a member of the recently identified Toll-like receptor family of proteins and has been putatively identified as Lps, the gene necessary for potent responses to lipopolysaccharide in mammals. In order to determine whether TLR4 is involved in lipopolysaccharide-induced activation of the nuclear factor-kappaB (NF-kappaB) pathway, HEK 293 cells were transiently transfected with human TLR4 cDNA and an NF-kappaB-dependent luciferase reporter plasmid followed by stimulation with lipopolysaccharide/CD14 complexes. The results demonstrate that lipopolysaccharide stimulates NF-kappaB-mediated gene expression in cells transfected with the TLR4 gene in a dose- and time-dependent fashion. Furthermore, E5531, a lipopolysaccharide antagonist, blocked TLR4-mediated transgene activation in a dose-dependent manner (IC50 approximately 30 nM). These data demonstrate that TLR4 is involved in lipopolysaccharide signaling and serves as a cell-surface co-receptor for CD14, leading to lipopolysaccharide-mediated NF-kappaB activation and subsequent cellular events.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10196138     DOI: 10.1074/jbc.274.16.10689

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  511 in total

1.  Commensal-associated molecular patterns induce selective toll-like receptor-trafficking from apical membrane to cytoplasmic compartments in polarized intestinal epithelium.

Authors:  Elke Cario; Dennis Brown; Mary McKee; Kathryn Lynch-Devaney; Guido Gerken; Daniel K Podolsky
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

2.  The lipopolysaccharide co-receptor CD14 is present and functional in seminal plasma and expressed on spermatozoa.

Authors:  C L Harris; M A Vigar; J E Rey Nores; V Horejsi; M O Labeta; B P Morgan
Journal:  Immunology       Date:  2001-11       Impact factor: 7.397

Review 3.  Lipopolysaccharide endotoxins.

Authors:  Christian R H Raetz; Chris Whitfield
Journal:  Annu Rev Biochem       Date:  2001-11-09       Impact factor: 23.643

4.  Endothelium-derived Toll-like receptor-4 is the key molecule in LPS-induced neutrophil sequestration into lungs.

Authors:  Graciela Andonegui; Claudine S Bonder; Francis Green; Sarah C Mullaly; Lori Zbytnuik; Eko Raharjo; Paul Kubes
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

Review 5.  The potential of the microbiota to influence vaccine responses.

Authors:  David J Lynn; Bali Pulendran
Journal:  J Leukoc Biol       Date:  2017-12-28       Impact factor: 4.962

6.  Synthetic Toll-like receptor 4 agonist enhances vaccine efficacy in an experimental model of toxic shock syndrome.

Authors:  Garry L Morefield; Lynn D Hawkins; Sally T Ishizaka; Teri L Kissner; Robert G Ulrich
Journal:  Clin Vaccine Immunol       Date:  2007-08-22

7.  The role of disulfide bonds in the assembly and function of MD-2.

Authors:  Gregory E D Mullen; Margaret N Kennedy; Alberto Visintin; Alessandra Mazzoni; Cynthia A Leifer; David R Davies; David M Segal
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-17       Impact factor: 11.205

8.  Immunological responses against Salmonella enterica serovar Typhimurium Braun lipoprotein and lipid A mutant strains in Swiss-Webster mice: potential use as live-attenuated vaccines.

Authors:  Tie Liu; Rolf König; Jian Sha; Stacy L Agar; Chien-Te K Tseng; Gary R Klimpel; Ashok K Chopra
Journal:  Microb Pathog       Date:  2007-10-06       Impact factor: 3.738

9.  Poly (I:C) and LPS induce distinct immune responses by ovarian stromal fibroblasts.

Authors:  Mickey V Patel; Zheng Shen; Charles R Wira
Journal:  J Reprod Immunol       Date:  2018-05-09       Impact factor: 4.054

10.  Childhood nephrotic syndrome in relapse is associated with down-regulation of monocyte CD14 expression and lipopolysaccharide-induced tumour necrosis factor-alpha production.

Authors:  S P Chen; W Cheung; C K Heng; S C Jordan; H K Yap
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.